CELLINK AB (publ) (“CELLINK” or the “Company”) (CELLINK is listed on Nasdaq First North Growth Market under CLNK) announces that Nasdaq Stockholm’s listing committee has approved the Company’s application to be listed on Nasdaq Stockholm Main Market. The approval is conditional upon the fulfilment of customary conditions, among others that a prospectus is approved and registered by the Swedish Financial Supervisory Authority (“SFSA”). The trading of the Company’s shares on Nasdaq Stockholm Main Market is expected to commence on Monday April 20, 2020, and the last day of trading on Nasdaq First North Growth Market is expected to be Friday 17 April.
CELLINK’s shares will continue to be traded under the same ticker (CLNK) and ISIN code (SE0013647385). No new shares will be issued in connection with the listing. Shareholders of CELLINK do not need to take any action in connection with the listing on Nasdaq Stockholm Main Market.
The listing on Nasdaq Stockholm is expected to attract a broader group of investors and give CELLINK greater access to the Swedish and international capital markets. The listing on Nasdaq Stockholm Main Market is also expected to improve the ability for CELLINK to acquire new companies, raise capital and continue to pursue the organic growth strategy.
CELLINK’s Board of Directors and management believes that the listing on Nasdaq Stockholm is an important step in the development of the Company. The listing on Nasdaq Stockholm Main Market is expected to further increase the awareness about CELLINK from existing and new potential shareholders, customers and suppliers. For these reasons, the board of directors of CELLINK has made the assessment that a listing on Nasdaq Stockholm will support the Company’s next steps towards its long-term targets.
CELLINK has prepared a prospectus in connection with the admission of trading of the Company’s shares on Nasdaq Stockholm. The prospectus is expected to be approved and registered by the SFSA and published on CELLINK website, www.cellink.com, on, or around, Wednesday 15 April 2020.
Carnegie Investment Bank AB (publ) acts as financial adviser to Cellink in connection with the listing on Nasdaq Stockholm. Advokatfirman Vinge KB acts as the Company’s legal adviser.
This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on April 3, 2020, at 15.30 CEST.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone (Sweden): +46 73 267 00 00 Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected]